Protein Summary
Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which is proposed to facilitate the transition from abortive to productive elongation by phosphorylating the CTD (carboxy-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). (Microbial infection) In case of HIV or SIV infections, binds to the transactivation domain of the viral nuclear transcriptional activator, Tat, thereby increasing Tat's affinity for the transactivating response RNA element (TAR RNA). Serves as an essential cofactor for Tat, by promoting RNA Pol II activation, allowing transcription of viral genes. This gene encodes a member of the highly conserved cyclin C subfamily. The encoded protein tightly associates with cyclin-dependent kinase 9, and is a major subunit of positive transcription elongation factor b (p-TEFb). In humans, there are multiple forms of positive transcription elongation factor b, whic ...more
- ENST00000261900
- ENSP00000261900
- ENSG00000129315
- ENST00000417344
- ENSP00000399845
- ENST00000618666
- ENSP00000481035
- CCNT
- CYCT1
- HIVE1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
drug perturbation | 0.96 | ||
interacting protein | 0.96 | ||
pathway | 0.96 | ||
transcription factor binding site profile | 0.95 | ||
biological process | 0.86 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 242.46 (req: < 5)
Gene RIFs: 80 (req: <= 3)
Antibodies: 255 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 242.46 (req: >= 5)
Gene RIFs: 80 (req: > 3)
Antibodies: 255 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 24
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 182
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0